Two new "breakthrough" drugs to treat breast cancer have been given the green light for use on the NHS.
The National Institute for Health and Care Excellence (NICE) approved palbociclib and ribociclib after negotiating prices for the treatments.
Research shows the drugs slow down advanced cancer for at least 10 months and can delay the need for chemotherapy.
Around 8,000 people in England will now have access to the medications.
There are about 45,000 new diagnoses of breast cancer in the country each year.
Palbociclib had earlier been rejected by NICE because of its high cost.
One cycle of palbociclib - or 21 capsules - costs £2,950 for a pack of 21. For 63 tablets of ribociclib, the price is the same.
Read the article on the BBC.com website here:
This new cancer drug will give women 'more time'. Thousands of women with previously untreatable breast cancer have been given a chance to take a new drug that could make a big impact on their lives.
The drug is called Palbociclib and it's one of a class of drugs described by one expert as "the most important breakthrough for women with advanced breast cancer in the last two years." Craig Eagle is head of oncology at Pfizer UK.
Share this post